MU-MA402C is under clinical development by T Cell Nouveau and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MU-MA402C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MU-MA402C overview

MU-MA402C is under development for the treatment of MAGE A4-positive, HLA-A 02:01-positive, unresectable, advanced or recurrent solid tumors. The therapeutic candidate comprises T-cells which are genetically engineered to express chimeric antigen receptors (CAR) targeting melanoma associated antigen 4 (MAGEA4) expressing cancer cells. It is administered parenterally.

T Cell Nouveau overview

T Cell Nouveau is a clinical stage biopharmaceutical company that focuses on cure of solid tumors with Hybrid CAR-T cell therapies to enhance the immune system with technology and offers other services. The company is headquartered in Chuo-ku, Tokyo, Japan.

For a complete picture of MU-MA402C’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.